SABR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SABR is not a good buy right now for an impatient investor. Despite a small near-term momentum improvement (MACD turning positive) and bullish-looking options positioning (calls favored), the broader trend remains bearish (SMA200 > SMA20 > SMA5) with no fresh news catalysts and a recent quarter showing weak profitability quality. If you must act immediately, the risk/reward favors staying out (hold/avoid) rather than buying into a still-downtrending chart.
Price is $1.27 (+4.13% today) while the broader market is weak (S&P 500 -0.58%). Momentum is trying to stabilize: MACD histogram is positive (0.00304) and expanding, suggesting a short-term bounce attempt. RSI(6) at ~47 is neutral—no oversold squeeze signal. However, the moving-average stack is decisively bearish (SMA200 > SMA20 > SMA5), which typically indicates rallies are more likely to fade than trend. Key levels: Pivot 1.282 is the immediate battle line (price is slightly below it). Resistance sits at 1.358 then 1.406; support is at 1.206 then 1.158. A clean break/hold above 1.358 would improve the buy case; losing 1.206 would likely restart downside pressure. Pattern-based probability is modest: ~40% chance of about +0.93% next day, +2.3% next week, +1.73% next month—no strong edge.
Intellectia Proprietary Trading Signals
Short-term momentum improvement (MACD positive/expanding) can support a tactical bounce.
Options market positioning is call-heavy (bullish sentiment).
Revenue is still growing modestly (+3.45% YoY in 2025/Q3).
Upcoming earnings (QDEC 2025 on 2026-02-19 pre-market) can act as an event catalyst if results/guide surprise positively.
Primary trend remains bearish (SMA200 > SMA20 > SMA5), which often caps rallies.
Extremely high IV (~104%, 90th percentile) signals elevated uncertainty and higher odds of sharp moves against new buyers.
Profitability quality looks weak in the latest quarter with major YoY declines in net income and EPS.
No supportive news flow in the last week; no clear near-term narrative catalyst.
Hedge funds and insiders show neutral activity—no strong "smart money" confirmation.
Latest reported quarter: 2025/Q3. Revenue increased to $715.183M (+3.45% YoY), showing modest top-line growth. However, profitability deteriorated sharply: net income fell to $848.744M (down -1451.12% YoY) and EPS dropped to 1.98 (down -1337.50% YoY). Gross margin also slipped to 56.22% (down -2.02% YoY). Overall, the quarter shows growth in revenue but weakening margins/earnings trends, which does not strongly support chasing the stock during a bearish technical phase.
No meaningful SABR-specific analyst trend can be concluded from the provided item (it references Citi and 'Alpha Tau,' not Sabre). Based on the dataset here, there are no clear recent rating upgrades/downgrades or price-target changes for SABR to lean on. Wall Street pros/cons view from available info: Pros—modest revenue growth and potential event catalyst at upcoming earnings; Cons—downtrending chart, high uncertainty priced into options, and weak/unstable profitability signals. Politicians/congress: no recent congress trading data available.
